Know Cancer

or
forgot password


Phase 2
18 Years
80 Years
Not Enrolling
Both
Myelodysplastic Syndrome

Thank you

Trial Information

Inclusion Criteria


- Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not
therapy related.

- Patient must be able to adhere to the study visit schedule and other protocol
requirements.

- Patient must understand and voluntarily sign an informed consent document.

- Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
test.

- Women must not be pregnant or lactating.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

CC-1088-MDS-801-001

NCT ID:

NCT00045786

Start Date:

October 2001

Completion Date:

November 2005

Related Keywords:

  • Myelodysplastic Syndrome
  • myelodysplastic syndrome
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Rush-Presbyterian-St Luke's Medical CenterChicago, Illinois  60612-3515